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Abstract: Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory
and immune-modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is
approved and registered for the treatment of psoriasis and Relapsing-Remitting Multiple Sclerosis
(RRMS). Psoriasis and RRMS share an immune-mediated aetiology, driven by severe inflammation
and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly
prescribed first-line agents with favourable safety and efficacy profiles. The potential benefits of FAEs
against other diseases that appear pathogenically different but share the pathologies of oxidative
stress and inflammation are currently investigated.
Keywords: clinical application; dimethyl fumarate; disease; fumaric acid esters; oxidative stress;
inflammation; Nrf2; disease
1. Introduction
Dimethyl fumarate (DMF) is a methyl ester of fumaric acid (FA) (i.e., an FA ester (FAE)) registered
for the treatment of relapsing forms of Multiple Sclerosis (MS) [1,2] and psoriasis [3,4]. As an α,
β-unsaturated carboxylic ester generated by reacting FA with methanol in the presence of sulfuric
acid, DMF notably stimulates mitochondrial tricarboxylic acid (TCA) cycle activity and adenosine
triphosphate (ATP) production [5]. Whilst FA alone is poorly absorbed in the gastrointestinal (GI) tract,
DMF and its active metabolite monomethyl fumarate (MMF) to which it is almost entirely converted
in the gut [6], have robust bioavailability (for pharmacokinetics data see [6]) and exert beneficial
effects in diseases characterised by inflammation [7–9], neurodegeneration [10,11] and toxic oxidative
stress [9,12]. A modernized version of DMF has recently been developed in diroximel fumarate (DRF),
which has comparable efficacy against MS to DMF but with fewer side effects [13].
The therapeutic efficacy of FAEs appears to be mediated through the activation of the nuclear
factor erythroid 2-related factor 2 (Nrf2) transcriptional pathway [14–16] as well as interaction with the
anti-inflammatory hydroxycarboxylic acid receptor 2 (HCAR2) [17,18]. The Nrf2 pathway is considered
a critical cellular defence system that responds to potentially toxic stimuli via the upregulation of
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antioxidant and Phase II cytoprotective response genes [19,20]. A number of Nrf2 inducing drugs have
been developed and tested in clinical [1,21–24] and pre-clinical [25–29] studies over the past decade
and many have demonstrated potential for clinical progression. These studies highlight the broad
therapeutic utility of targeted Nrf2 activation against a variety of diseases (summarised in Table 1).
In addition to the activation of Nrf2, MMF also interacts with HCAR2, which strongly modulates
anti-inflammatory activity, particularly in primary and accessory immune cells [30]. By reversing
mitochondrial TCA cycle flux, there is novel evidence that FAEs might exert at least a portion of
their immunomodulatory action through generating succinyl-carnitine esters or other metabolites as
well [31,32]. The collective Nrf2-inducing and immuno-modulatory properties of DMF and other FAEs,
have demonstrated therapeutic efficacy across multiple body systems such as the central nervous [10,33],
cardiovascular [34,35], gastrointestinal [7,36,37], immune [5,38] and integumentary [39,40] systems.
Thus, the prospective clinical impact of DMF and its esters is extensive.
Table 1. Summary of fumaric acid esters either approved for human use, previously tested or currently
examined in human/animal trials.
Status Compound Disease Phase of Trial




Diroximel Fumarate Multiple Sclerosis Approved
Monomethyl Fumarate Multiple Sclerosis Approved
Human Trials Dimethyl Fumarate
Amyotrophic Lateral Sclerosis Phase II
Cutaneous T Cell Lymphoma Phase II
Glioblastoma Multiforme Phase II
Obstructive Sleep Apnoea Phase II













This review discusses the efficacy and side-effect profiles of FAEs with reference to reported data
from completed and ongoing clinical and pre-clinical trials and postulates new clinical indications.
2. Approved Indications for Dimethyl Fumarate (DMF)
Oxidative stress occurs when oxidant production (i.e., reactive oxygen species (ROS)) exceeds the
capacity of endogenous antioxidants to scavenge and detoxify ROS, and generally leads to oxidative
cellular damage [41,42]. ROS can oxidise biomolecules and structurally modify proteins and DNA
to trigger signalling cascades that both cause and progress tissue damage and inflammation [41].
Although inflammation is an ostensibly beneficial response to tissue injury in which immune cells
are recruited to digest necrotic tissue and promote new tissue regeneration, chronic inflammation
potentiates oxidative stress and tissue injury through persistent inflammatory cytokine release [43].
In response to cytokines, immune cells generate more ROS, escalating oxidative stress and insult to
tissues [43]. This paradoxical interrelation between oxidative stress and inflammation has been linked
to many chronic inflammatory diseases including psoriasis and MS. The efficacy of FAEs is proposed
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to be based on their dual antioxidant and anti-inflammatory effects, which justifies the global approval
of FAE drugs for both indications.
2.1. DMF for Psoriasis
Psoriasis is a non-contagious, chronic, multi-system inflammatory skin disease characterised
by recurrent episodes of red, scaly skin plaques that are distinctively demarcated from the normal
underlying skin [44]. DMF and its utility as a treatment for psoriasis were conceptualised in the late
1950s based on the inaccurate assumption that skin disease was initiated by a TCA cycle biochemical
defect and that exogenous administration of FA, an intermediate TCA cycle product, could re-establish
its balance [45]. Whilst free FA is poorly absorbed by the GI tract [46], Altmeyer et al. [47] demonstrated
that its ester derivatives, MMF and DMF, were beneficial to treat psoriasis in 100 patients in a
randomised double-blind study. Following this, an FA mixture comprised largely of DMF (60%) and
three ethyl hydrogen fumarates (calcium, magnesium and zinc salts of monoethyl fumarate (MEF))
were approved for the treatment of moderate and severe forms of psoriasis under the brand name
Fumaderm® [48]. DMF was ultimately discovered to be the bioactive component in the preparation [49]
since MEF salts alone exerted no significant clinical efficacy [50]. More recently, a DMF-only formulation,
Skilarence®, was approved by the European Medicines Agency as it provided comparable efficacy
and safety profiles to that of Fumaderm® in a Phase III double-blind, placebo-controlled trial with
671 patients (NCT01726933) [40]. While the aetiology of psoriasis is still not fully elucidated, it is
classified as an immune-mediated disorder owing to a combination of genetic, immunological and
environmental factors [51]. As the complex interaction between these three immunomodulatory factors
has become better characterised [52–54], the primary mode of action (MOA) of DMF was established
as immunomodulation [55,56]. In light of this, as well as DMF’s robust efficacy [39,40] and acceptable
safety [39,57] profile, the prospect of utilising FAEs for other diseases that share an immune-mediated
origin with psoriasis, such as MS, was proposed.
2.2. DMF for Multiple Sclerosis (MS)
Owing to their success in treating psoriasis, Schilling et al. [58] investigated FAEs in the
experimental autoimmune encephalomyelitis mouse model, which reproduces several of the typical
features of human MS. This study revealed therapeutic effects of FAEs prompting further investigation
and clinical studies with DMF, specifically in MS patients. MS is a chronic inflammatory demyelinating
disorder of the central nervous system characterised by dysregulation of innate and adaptive immune
responses [59]. Relapsing-Remitting MS (RRMS) is the most common MS subtype, characterised
as a clear increase in new or existing neurological symptoms followed by periods of incomplete or
complete recovery, termed remissions. The first exploratory clinical trial of FAE in RRMS took place in
2006 where Fumaderm® was given to 10 patients [60]. Although this study was a small, open-label
pilot study, FAEs induced promising improvements in both radiological and clinical parameters and
paved the way for continuing clinical trials with DMF. BG-12, an orally administered, enteric-coated
micro tablet slow-release preparation of DMF [38] (marketed as Tecfidera®), was formulated to
reduce GI-related side effects including diarrhoea and nausea and trialled in one Phase II [2] and
two subsequent Phase III trials [1,61]. In 2008, the Phase IIb clinical trial (NCT00168701) established
efficacy and safety of several different dosages of the delayed release formulation [2]. BG-12 reduced
the number of new lesions as well as decreased annualised relapse rates compared to the placebo [2].
These favourable results prompted further long-term Phase III studies in a larger group of patients
with RRMS. In 2012, the Determination of the Efficacy and Safety of Oral Fumarate in RRMS (DEFINE;
NCT00420212) [1] and Comparator and an Oral Fumarate in RRMS (CONFIRM; NCT00451451) [61]
studies were published. Over their 2-year duration, these multicentre, placebo controlled, double
blind clinical trials proved that daily treatment of BG-12 decreased the rate of disease progression,
number of lesions (observed via magnetic resonance imaging) and significantly reduced the proportion
of relapsing patients [1,61]. Although the safety and tolerability of DMF were deemed acceptable in
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these trials, the incidence of side effects such as flushing, as well as GI events including diarrhoea,
upper abdominal pain, vomiting and nausea, were commonly reported by patients in the first month
of treatment. Thereafter, the number of side effects reported by patients reduced significantly [62].
While flushing is associated with increased prostaglandin production through key MOA agonism of
HCAR2, GI symptoms are the primary reason for treatment discontinuation [63,64] and attributable to
the action of major metabolite methanol on small intestine mucosa [63]. Progress toward improved
formulations/molecules to minimise GI-related side effects, whilst maintaining the efficacy of DMF
have recently been made.
Diroximel fumarate (DRF) (marketed as Vumerity®), is a novel orally administered FAE, approved
in late 2019 for the treatment of relapsing forms of MS. Approval was based on data from an open-label,
Phase III study (NCT02634307) that demonstrated long-term safety and efficacy [63] in addition
to another study (NCT03093324) that compared Vumerity® against Tecfidera® [13]. The proposed
mechanism through which DRF could improve gut tolerability compared to DMF was through
substitution of DMF’s methanol leaving group with inert 2-hydroxyethyl succinimide (HES) [63].
Upon oral administration, DMF is cleaved by gut esterases to yield the major metabolites MMF
and methanol; whereas DRF undergoes esterase cleavage to yield major metabolites MMF and HES
as well as minor metabolites RDC-8439 and methanol [63]. Otherwise, DRF shares a comparable
pharmacokinetic profile to DMF [65]. DRF was shown to be well-tolerated with fewer GI reactions
in comparison to DMF in the study [13]. At therapeutic doses, DRF and DMF yielded bioequivalent
production of the active metabolite MMF, which has been proposed to exert most of the efficacy
imparted by FAEs in MS patients [13]. Another DMF bioequivalent, Bafiertam™ (MMF) was recently
approved (April 2020) for RRMS. Since a lower dose of Bafiertam™ is required compared to Tecfidera®
to produce equivalent plasma MMF levels, reduced adverse effects have been purported. Although
Bafiertam™ was not independently evaluated in clinical trials with MS patients, it has been approved
based on DMF’s efficacy in RRMS. It is possible that FAEs might also be useful to treat diseases that,
like psoriasis and MS, are associated with oxidative stress and/or inflammation: this has been an area
of intense clinical and pre-clinical research over the past decade.
3. Clinical Trials (Novel Indications)
FAEs including DMF/MMF and DRF proved to be valuable therapeutics against psoriasis
and MS. In particular, DMF was shown to activate the intrinsic cellular response to oxidative
stress [66] and counteract cytotoxic insult [67] to promote cell survival. For these reasons, DMF and
its esters are purported to afford therapeutic benefits in other diseases complicated by oxidative
stress and inflammation, such as amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative,
inflammatory disorder that results in progressive paralysis and death from respiratory failure within
2–3 years [68]. Although the aetiology of ALS lies in the progressive degeneration of motor neurons,
innate immune responsivity has been implicated in the initiation and progression of the disease [69,70].
Reduced levels of regulatory T cells in conjunction with increased macrophage activation [70] and
pro-inflammatory effector T cells and cytokines [71] are indicators of rapid disease progression in ALS.
Tecfidera® (DMF) increased the ratio of anti-inflammatory to pro-inflammatory T-cell subsets [72,73]
and reduced pro-inflammatory T cells in RRMS [72], resulting in enhanced anti-inflammatory activity
and neuroprotection. Based on these encouraging results, Vucic et al. (2020) are currently undertaking
a Phase II randomised, double blind clinical trial (ACTRN12618000534280) to assess the efficacy and
safety of Tecfidera® in patients with ALS. The trial commenced in 2018 with anticipated results in late
2020 or early 2021 [74].
A Phase II clinical trial for Cutaneous T Cell Lymphoma (CTCL) is also currently underway with
a projected end date of late 2021 (NCT02546440). CTCLs are a heterogeneous group of non-Hodgkin’s
lymphomas characterised by cutaneous infiltration of malignant monoclonal T lymphocytes [75].
Previous pre-clinical trials proposed that DMF inhibits tumour growth and distant metastasis,
and restores sensitivity of CTCL cells towards apoptosis by down-regulating elevated nuclear factor
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κ-light-chain-enhancer of activated B cells (NF-κB) [76]. NF-κB is a transcription factor protein complex
involved in inflammation, immune responsiveness and apoptosis [77]. Since apoptosis re-sensitisation
was only detected in tumour cells (and not healthy lymphocytes) [76], DMF could be an attractive
disease modifying co-treatment candidate in CTCL due to its inherent lack of toxicity and favourable
safety profile.
Obstructive sleep apnoea (OSA) is a common disorder that involves collapse of the upper
airway during sleep, which results in low blood oxygen levels and sleep disruption when left
untreated. OSA increases the risk of cardiovascular-related complications including high blood
pressure, heart disease and stroke [78]. OSA has been consistently linked to inflammation, with elevated
pro-inflammatory cytokines and adhesion molecules in OSA patients [79–81], where systemic
hyperinflammation caused by other complications increases the severity of OSA [82]. Intermittent
hypoxia associated with OSA is acknowledged as a driver of inflammation [83,84], and at least partially
mediated by the activation of NF-κB [85]. FAEs inhibit NF-κB through activation of both Nrf2 and
HCAR2, and consequently, the secretion of pro-inflammatory molecules [17]. Studies have revealed a
formal association between the use of immunomodulatory/immunosuppressive agents and reduced
OSA severity and/or frequency [82,86]. As such, a Phase II randomised, placebo-controlled clinical trial
was initiated (NCT02438137) to determine whether DMF was effective for the treatment of OSA. In this
yet peer-reviewed study, DMF attenuated disease severity suggesting that OSA may be responsive to
agents that regulate immune signalling pathways. Suppression of systemic inflammation via NF-κB
reduction was hypothesised as the likely mediator of DMF’s efficacy in OSA.
Whilst DMF demonstrated efficacy in numerous clinical trials, it is important to highlight that
some studies failed to show therapeutic efficacy or were abandoned or terminated/withdrawn. A Phase
II study that commenced in 2008 trialled DMF (BG-12) in patients with active rheumatoid arthritis.
Although DMF activated the Nrf2 pathway eliciting a downward trend for some inflammatory markers
and cytokines, it did not significantly modify the pre-defined end-point outcome measures (unpublished
clinical trial data; NCT00810836). Another study that investigated the therapeutic potential of DMF in
systemic sclerosis-associated pulmonary arterial hypertension (NCT02981082) was terminated due to
low recruitment numbers. Similarly, due to lack of funding, a trial investigating the efficacy, safety
and tolerability of DMF in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,
was terminated in 2019. Other completed studies include the use of DMF in glioblastoma multiforme
(NCT02337426) and cutaneous lupus erythematosus (NCT01352988) completed in 2017 and 2014,
respectively, with no results published.
4. Pre-Clinical Trials
Recently, Jadeja et al. [87] published a detailed overview of the pre-clinical literature evaluating
FAEs for the prevention and treatment of diseases in which oxidative stress and/or inflammation are
prominent (other than psoriasis and MS). As such, the pre-clinical studies of FAE will only be briefly
discussed here.
4.1. GI/Digestive Tract Indications
Inflammatory bowel disease (IBD) is a collection of disorders that are characterised by dysfunction
of mucosal immune response and abnormal cytokine production, which contributes to chronic
inflammation in the digestive tract [7]. Although there is a range of treatment options available for
diseases associated with IBD, given the complex aetiology, the demand for novel and/or improved
therapeutic strategies remains high. Since there is a well-established association between IBD
development/progression and inflammation, several groups have sought to investigate the efficacy of
FAE in the treatment of GI-associated disorders. In most instances, experimental rodent models of
colitis have been used to demonstrate the efficacy of DMF for mitigating colon injury, pro-inflammatory
cytokine and adhesion molecule production and NF-κB signalling [7]. Furthermore, DMF exerts efficacy
in IBD through induction of the Nrf2-mediated antioxidant response involving increased superoxide
Pharmaceuticals 2020, 13, 306 6 of 15
dismutase (SOD) expression to reduce lipid peroxidation [7,36]. MMF has also been shown to suppress
or completely prevent gastric ulceration in rats [88] highlighting FAEs as potent gastro-protective
agents. Together, studies like these surprisingly indicate that DMF/MMF and other FAEs may be of
clinical benefit for GI indications, despite themselves eliciting GI side effects particularly in the initial
stages of treatment [2,57,63,89]. The beneficial effects of FAEs appear to also extend beyond the GI tract.
Both MMF [90] and DMF [91] exhibited hepatoprotective effects in various models of hepatotoxicity by
reducing inflammation and oxidative stress. Larger studies to further develop/refine the efficacy of
FAE formulations in GI and hepatic conditions are warranted to establish their clinical potential.
4.2. Neurological Indications
The brain is especially sensitive to perturbations caused by oxidative and/or inflammatory
stress. In fact, these factors are central to the pathogenesis of several neurodegenerative diseases
including Alzheimer’s disease (AD) [33,92], Parkinson’s disease (PD) [93], Huntington’s disease (HD)
and intracerebral haemorrhage (stroke) [94]. Concomitantly, these diseases are also underscored by
pathological mitochondria and perturbations in energy homeostasis (reviewed in [95,96]). Therefore,
therapies that enhance anti-oxidative potential, counter stressors and promote mitochondrial pool
maintenance and function may be of clinical value. FAE can induce Nrf2 signalling and cellular
defence machinery against oxidative stress [67], which should therefore provide some neuroprotection
in disorders such as AD, PD and HD. In mouse models of these diseases, DMF reduced damage
and degeneration to preserve neuronal populations [10,33,97,98] by upregulating Nrf2-dependent
antioxidant genes [10,97] and suppressing NF-κB-mediated inflammation [10,69,70,97]. These molecular
adaptations attenuated clinical symptoms including motor impairment [69], long-term memory
deficits [70] and increased overall survival rates [69]. One downstream response to Nrf2 activation is
mitochondrial biogenesis through key regulators, peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC1α) and mitochondrial transcription factor A (TFAM) [99]. Pharmacological
up-regulation of mitochondrial biogenesis and turnover has shown therapeutic value in mouse
models of PD and HD [95] and mitochondrial function stimulants have shown similar pre-clinical
benefits in AD [96]. Since DMF can stimulate mitochondrial substrate flux, anaplerosis and energy
production during its endpoint metabolism (i.e., fumarate) in the mitochondrial TCA cycle, as well as
activate Nrf2, it could exert additional therapeutic activity in this regard. DMF was also beneficial in
ischemia-related pathogenesis such as that elicited through stroke, where neuroprotection and neuronal
survival can be enhanced to avert ischemic injury. In mouse [100,101] and rat [102] models of stroke,
DMF reduced ischemia-associated inflammation [100–102], stabilised the blood brain barrier [100,101],
prevented cerebral oedema [71,101,102], enhanced neurological recovery [71,101,102] and importantly,
ameliorated neurological deficits and improved hematoma resolution even when administered as late
as 24 h after the haemorrhage event [102]. These pre-clinical studies highlight the clinical potential for
FAEs to be repurposed for neurodegenerative and ischemia-related disorders of the brain.
4.3. Cancer Related Indications
Accumulating evidence suggest that DMF exerts anti-tumorigenic properties in several types of
cancers. DMF was first implicated in the inhibition of cancer cell growth in the early 2000s when its
effect on melanoma growth and metastasis was evaluated in animal models and human melanoma cell
lines [103]. This work was supported by the discovery that DMF reduces cell invasion and metastasis
of melanoma cells by inhibiting pro-metastatic proteases such as the matrix metalloproteinases
(MMPs) [104,105], as well as by inducing apoptosis and cell cycle inhibition [105,106]. More recently,
Takeda et al. [105] proposed that DMF prolongs survival in melanoma mouse models and exerts its
anti-metastatic efficacy through suppression of nuclear translocation of NF-κB. NF-κB is constitutively
active in several types of cancer [107–109]. Especially in breast cancer, NF-κB signalling enhances
tumour cell survival, migration, invasion, angiogenesis and resistance to anti-cancer therapy [110,111].
NF-κB is thus a prognostic indicator of aggressive breast cancers [111]. Consistent with its anti-NF-κB
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activity, DMF inhibited mammosphere formation (a functional measure of cancer stem cell properties),
cell proliferation and xenograft tumour growth [110], providing proof-of-concept evidence for the
clinical potential of DMF in breast cancer therapy. Other cancer cell lines, including colorectal
cancer [37], cervical cancer [112], lung adenocarcinoma [113] and pancreatic carcinoma [113] are also
sensitive to DMF-induced cytotoxicity. These studies suggest that FAE could be broadly utilised as an
anti-cancer therapy.
4.4. Cardiovascular Indications
The role of oxidative stress in the aetiology of vasculopathy and hypertension is well-
documented [114]. Excessive ROS production diminishes nitric oxide bioavailability, leading to
increased vasoconstriction and damage to the vasculature by inducing inflammation and fibrosis [115].
Although the specific MOA remains to be determined, the cardioprotective effect of fumarate has
been associated with its metabolism to succinate through both oxidative and reductive pathways.
This was confirmed by Laplante et al. [116] where metabolic fluxes in fumarate-perfused rat hearts
were studied. Since then, some evidence has emerged to suggest that DMF may be useful for
cardiovascular related indications. Grzegorzewska et al. [34] demonstrated in mouse models of
pulmonary arterial hypertension and lung fibrosis that DMF reduced inflammation, oxidative damage
and fibrosis. DMF also attenuated abnormal remodelling after acute vascular injury in rat carotid
arteries [35]. Whilst these studies suggest that FAE might be beneficial for patients with vascular
diseases, more research is warranted to establish DMF efficacy for these indications.
5. Novel Applications
The combined Nrf2-inducing and immune-modulatory properties of FAE and their robust
bioavailability have enabled drugs such as DMF and MMF to be versatile across pathologies in a
range of body systems (summarised in Figure 1). Thus, the potential clinical impact of FAE therapy
is high and particularly broad. The evidence provided in this review, as well as by others [45,49,87],
compellingly demonstrates that, since oxidative stress and inflammation are inextricably linked, FAEs
have the potential to positively influence diseases characterised by both of these factors. This could
include chronic and progressive neuromuscular diseases such as Duchenne and Becker Muscular
Dystrophy; mitochondrial diseases such as Friedreichs’s Ataxia as well as other diseases featuring
mitochondrial dysfunction; respiratory-related diseases including novel coronavirus (COVID-19)
since it has recently been proposed that severely affected patients manifest a cytokine storm
syndrome [117] and treatment of hyperinflammation may reduce mortality rate; renal diseases
including glomerulonephritis and; metabolic disorders such as diabetes. Less potent Nrf2 activators
(sulforaphane [26,118], curcumin [25,119,120] and resveratrol [27,28,121]) have been developed, tested
and demonstrated for use in some of these indications, however do not appear to exert the same
influences on innate and adaptive immunity as FAEs. Since FAEs such as DMF are approved, affordable,
widely available and clinically well characterised, they are appealing candidates for expanded clinical
development. As such, exploratory trials of FAE therapies in a variety of other diseases is warranted
(Figure 1).
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Figure 1. Approved and evidenced utility of dimethyl fumarate (DMF) and fumaric acid esters (FAE)
versus potential utility in other diseases that are underscored by oxidative stress and hyperinflammation.
DMF and FAE can exert their effects by enhancing cytoprotective and anti-inflammatory responses.
This is proposed to lead to the reduction of reactive oxygen species (ROS), which in turn prevents
oxidative tissue damage. DMF also inhibits nuclear factor κ-light-chain-enhancer of activated B cells
(NF-κB), which subsequently reduces pro-inflammatory cytokine production and immune cell deviation
and ultimately leads to reduced inflammation. BMD: Becker Muscular Dystrophy; COPD: chronic
obstructive pulmonary disease; DMD: Duchenne Muscular Dystrophy; IBD: inflammatory bowel
disease; SLE: systemic lupus erythematosus. Bar heads = inhibitory effect; Arrow heads = potential
beneficial effect. Created with BioRender.com.
6. Conclusions
FAEs are currently approved for several indications including psoriasis and RRMS, due to
their anti-inflammatory, anti-oxidative and immunomodulatory properties and are investigated for
many other indications. FAEs are drugs with broad clinical utility and favourable safety profiles,
which could be quickly expanded to treat other diseases with unmet clinical needs through drug
repurposing strategies.
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